Baird analyst Catherine Ramsey Schulte raised the firm’s price target on Caris Life Sciences (CAI) to $28 from $26 and keeps an Outperform rating on the shares. The firm updated its model following solid Q4 results and a 2026 outlook that surpassed expectations.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAI:
- Caris Life Sciences price target lowered to $34 from $38 at Evercore ISI
- Caris Life Sciences price target lowered to $38 from $45 at BTIG
- Caris Life Sciences price target raised to $28 from $26 at Baird
- Caris Life Sciences price target lowered to $35 from $40 at JPMorgan
- Caris Life Sciences price target lowered to $35 from $42 at Citi